November 11, 2021 10:52 AM EST
News Briefing

Kaléo to pay out more than $12M in false claims case re­gard­ing high-priced ver­sion of cheap opi­oid over­dose an­ti­dote; Uro­Gen gets ready to start PhI­II can­cer tri­al

Paul Schloesser

Associate Editor

Vir­ginia phar­ma Kaléo has agreed to pay the Unit­ed States $12.7 mil­lion to re­solve ac­cu­sa­tions that the phar­ma caused the sub­mis­sion of false claims for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times